Browsing Tag
Albert Bourla
11 posts
Pfizer beats Q2 2025 earnings expectations and raises profit forecast, but long-term growth questions persist
Pfizer beats Q2 2025 estimates and raises profit guidance, but patent expirations and pricing pressures keep long-term growth questions on the table.
Pfizer reports strong Q4 2024 earnings, reaffirms 2025 guidance amid cost-cutting strategy
Pfizer Inc. delivered strong fourth-quarter 2024 earnings, exceeding analyst expectations and demonstrating resilience in a challenging pharmaceutical market.…
Pfizer stuns Wall Street with booming Q3 earnings and new guidance boost
Pfizer Inc. delivered a financial jolt in its third quarter of 2024, surpassing Wall Street’s expectations and raising…
Pfizer gets PAXLOVID FDA approval for COVID-19 in high-risk adults
Pfizer has obtained approval for PAXLOVID, an oral combination therapy of nirmatrelvir tablets and ritonavir tablets, from the…
Pfizer to acquire cancer-focused drugmaker Seagen in $43bn deal to expand oncology leadership
Pfizer is set to acquire Seagen for $43 billion in cash to boost its oncology drug pipeline and antibody-drug conjugate capabilities. Learn how the deal reshapes cancer therapeutics.
FDA grants EUA for Omicron-adapted Covid-19 vaccine for children below five
Pfizer and BioNTech have received the US Food and Drug Administration (FDA) emergency use authorization (EUA) for their…
Pfizer to acquire Oxbryta developer Global Blood Therapeutics for $5.4bn
Pfizer has agreed to acquire Global Blood Therapeutics (GBT), a publicly-listed American biopharma company, in a deal worth…
Pfizer and BioNTech’s COVID-19 vaccine secures FDA emergency use authorization
In a groundbreaking move, Pfizer and BioNTech have received emergency use authorization (EUA) from the US Food and…
UK grants emergency authorization for Pfizer and BioNTech’s BNT162b2 Covid-19 vaccine
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted emergency use authorization (EUA) for the BNT162b2…
Pfizer and BioNTech’s Covid-19 vaccine candidate shows over 90% effectiveness in Phase 3 Trial
Pfizer and BioNTech have announced a groundbreaking update in their efforts to combat the Covid-19 pandemic. Their BNT162b2…